#China #Shanghai #oncology #Asieris Pharma #APL-1702

Asieris Pharmaceuticals Reports Strong Growth in 2024

Asieris Pharmaceuticals has recently unveiled its annual report for 2024, illustrating a noteworthy achievement with revenues surpassing RMB 200 million within its inaugural year of commercialization. This milestone reflects the company’s dedicated strategy focusing on specialty pharmaceuticals and operational efficiency. The report underlines how the company not only met its commercialization goals but also made considerable advancements in its innovative drug portfolio, which includes APL-1702 and APL-1706 (Hexvix®), both primed for market launch.

As of the end of the reporting period, Asieris boasted a robust financial position, holding approximately RMB 1.89 billion in liquid assets. This provides a significant foundation for continued investment in research and development (R&D), with a pipeline featuring 12 products undergoing development, coupled with 16 ongoing research projects.

Solid Revenue Growth and Operational Break-even

2024 marked Asieris' first full year of operations post-commercialization, during which it optimally executed market strategies while managing costs. The reported operating revenue of RMB 202 million highlights the company's successful steps towards achieving break-even in its commercial activities. Products such as Ouyoubi and Dipaite quickly gained traction, penetrating over 1,000 and 500 hospitals, respectively, with significant market share captured for both neratinib and pazopanib tablets.

In a bid to expand its footprint, Asieris has been strategically diversifying its offerings in women's health and urological tumors. A particularly exciting development came in March 2025, when Asieris licensed an eribulin mesylate injection aimed at treating advanced breast cancer, thereby strengthening its therapeutic lineup.

Innovation in Women's Health

APL-1702 represents a key component of Asieris's aggressive push into women's health. This novel combination of a drug and medical device targets the non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL). In May 2024, the product’s marketing application received acceptance from the National Medical Products Administration (NMPA), marking a significant step towards approval. APL-1702 has been designed to address the increasing prevalence of cervical intraepithelial neoplasia (CIN) in younger women, offering an innovative treatment option that focuses on fertility preservation.

Since initiating its market strategies, Asieris has conducted eight expert advisory meetings to foster support and enhance awareness about APL-1702 among healthcare professionals. These endeavors have yielded positive endorsements from leading specialists, emphasizing the potential impact of APL-1702 in the given therapeutic area.

Expedited Approval and Launch Strategies

On the urology front, Hexvix® received NMPA approval in November 2024, ahead of schedule. This product has attained recognition as the first diagnostic imaging agent in China for photodynamic blue light cystoscopy, enhancing bladder cancer diagnostic accuracy. Asieris's team is strategically orchestrating the launch process to target patients with commercial insurance and those willing to pay out of pocket, maximizing the product's reach to leading hospitals and clinics.

The Oncology Business Unit aims to optimize the adoption of Hexvix® while synchronizing efforts with top medical facilities to integrate advanced diagnostic procedures into general hospital protocols.

Future Prospects and Strategic Directions

Moving forward, Asieris plans to focus on expediting drug availability combined with robust R&D initiatives in high-priority areas, especially women’s health and oncology. Dr. Kevin Pan, the company's Founder and CEO, spoke passionately about 2024 being a significant year that has set up a robust foundation for accelerated growth in the coming years. He emphasized Asieris's commitment to generating groundbreaking therapies that meet unmet medical needs globally.

With strong pipelines and a strategic focus on global market expansion, Asieris aims to maintain its trajectory of impressive growth and innovative healthcare solutions, thereby delivering value for patients and stakeholders alike. The company is keenly aware of the growing demand for unique therapies that can address pressing health issues effectively, making it an exciting player in the biopharmaceutical landscape.

Asieris Pharmaceuticals continues to solidify its position in the sector, combining innovative treatment options with a rigorous strategy for commercialization and expansion.